ArticleDrug delivery2022

A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.

Shiming He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.